Neurofibromatosis type 1 (NF1) is a disorder affecting more than 100,000 people each year in the United States and is therefore the most common genetic tumor predisposition syndrome. NF1 can result in low grade gliomas (LGG) and less commonly high grade glioma (HGG). While some HGGs seem to arise spontaneously, there is evidence that some HGGs in patients with NF1 arise from LGGs. However, the genomic changes that take place during this transition are not well known. Researchers on this project aim to identify such genomic changes and to develop pre-clinical models. Pre-clinical models are used to study disease progression and drug interactions before therapeutics are administered to real patients. Development of strong models, especially those containing the genomic alterations associated with NF1 will allow for discovery of new therapies in the treatment of LGGs and HGGs. This team will use specimens prepared and provided by the Children’s Brain Tumor Network to pursue this research. This study will allow for the development of pre-clinical models that can be used to identify novel therapies for transformed NF1 gliomas.
What are the goals of this project?
Researchers aim to develop strong pre-clinical models for NF1 associated gliomas.
What is the impact of this project?
The development of pre-clinical models could lead to new treatment options for low grade and high grade glioma patients.
Why is the CBTN request important to this project?
The rare and high quality specimens available through the Children’s Brain Tumor Network are essential for the development of strong pre-clinical models.
Javad Nazarian, PhD, MSc
I am an investigator at the Center for Genetic Medicine in Children’s National Hospital in Washington, D.C., and an assistant professor in Integrative Systems Biology at the George Washington University. I received my PhD from the George Washington University in Genetics in 2005. My dissertation res
Children’s National Hospital
Children’s National HospitalJoined on
Each year, the Brain Tumor Institute at Children’s National evaluates more than 100 new patients with brain tumors, and is recognized as a world leader in childhood brain tumor care and research. Children’s National has pioneered novel pediatric brain tumor therapies, including new molecularly-targe